Background An increasing number of countries with low incidence of tuberculosis have pre-entry screening programmes for migrants. We present the fi rst estimates of the prevalence of and risk factors for tuberculosis in migrants from 15 high-incidence countries screened before entry to the UK.
Introduction
Medical screening of migrants for tuberculosis has been implemented for more than a century, but only recently have data been systematically obtained and analysed to understand its eff ectiveness. [1] [2] [3] Screening can occur before entry (ie, pre-entry screening), at entry (sometimes called port-of-entry screening), or after entry. Australia, Austria, Canada, France, Israel, Jordan, New Zealand, the UK, and the USA have pre-entry screening programmes for tuberculosis. 4 In our 2014 systematic review and meta-analysis, 2 we identifi ed substantial variation in protocols and detection rates of active infection, but the detection rates were in migrants from high-incidence countries. No UK data were included in this review.
Historically, the UK screened migrants before, at, and after entry. 5 In May, 2012, the UK Government announced the transition to a fully pre-entry system, expanding the screening programme from 15 pilot locations in operation from 2005, to 101 high-incidence countries (ie, those with a WHO-estimated prevalence of >40 cases per 100 000 population). This transition occurred in four phases and was completed on March 31, 2014 (appendix p 9). To improve international pre-entry screening programmes, we investigated the prevalence of and risk factors for tuberculosis in migrants from high-incidence countries screened before migration, using historical data from the 15 countries in the UK pilot programme.
Methods

Study design
We did a population-based cross-sectional study of migrants applying for visas to stay in the UK for more than 6 months, who were screened for tuberculosis before entry in 15 countries taking part in a pilot programme. We used data collected by the International Organization for Migration (IOM) between Oct 1, 2005 , and Dec 31, 2013, on behalf of the UK as part of the screening process and included demographic and clinical data for all individuals screened, including age, sex, self-report of close or household contact with an individual with tuberculosis before screening (defi ned as anyone in the household who has been diagnosed with tuberculosis in the past 2 years, or history of recent contact with an individual with active pulmonary tuberculosis who shared the same enclosed air space, household, or other enclosed environment for a prolonged period of days or weeks; appendix p 4), visa category, and whether the individual was screened at a clinic where culture testing was done. Data were obtained, collated, and cleaned by the IOM Health Research and Epidemiology Unit and Public Health England to ensure that records included all laboratory results of individuals screened. Data for WHO prevalence in migrants' country of origin were from 2010. 6 During the pilot phase of the pre-entry screening programme, culture testing for Mycobacterium tuberculosis was not available at all sites. To ensure comparability of estimates across countries and locations, we restricted the primary analysis to data from sites where culture and smear testing was done on all sputum samples. We removed duplicate screens according to rules in appendix p 3.
Ethics approval was received for this analysis from University College London Research Ethics Committee (3294/002). Public Health England has authority under the Health and Social Care Act 2012 to hold and analyse national surveillance data (including tuberculosis preentry screening programme data) for public health and research purposes.
Procedure
The UK tuberculosis technical instructions set out procedures for screening, with quality assurance provided by Public Health England. Briefl y, applicants aged 11 years or above received standard posteroanterior chest radiography, and all individuals with radiological fi ndings consistent with tuberculosis were required to undergo sputum testing (appendix p 1). Applicants who were unwilling or unable to have radiography (eg, pregnant women) were required to provide sputum specimens taken on three separate occasions, not less than 24 h apart and ideally in the early morning. Specimens were tested for M tuberculosis in designated laboratories by smear and culture. All specimens were examined under the micro scope for acidfast bacilli by an auramine stain (or, if necessary, by Ziehl-Neelsen stain). Specimens were cultured for a minimum of 6 weeks in liquid media or 8 weeks in solid media, unless a positive result was obtained earlier than these time periods. If no growth was detected after these time periods, specimens were reported as negative.
Applicants were issued with a clearance certifi cate if their chest radiographs were classifi ed as free of any radiological changes, or had minor fi ndings that were not associated with tuberculosis. Individuals diagnosed with active tuberculosis could restart the screening process after successful completion of a full course of approved treatment, but not within 6 months of the original screening examination.
Outcomes
The primary outcome was the prevalence of bacteriologically confi rmed tuberculosis, with cases specifi ed according to a WHO-revised defi nition of "one from whom a biological specimen is positive by smear microscopy or culture". 7 Secondary outcomes were prevalence of tuberculosis confi rmed by culture testing on liquid or solid
Research in context
Evidence before this study In 2014, we did a systematic review and meta-analysis of pre-entry screening for tuberculosis, which we have updated to identify new articles published until Nov 19, 2015 , by searching Medline and Embase with the same search terms, including "migrants", "pre-entry screening", and "tuberculosis". Only studies reporting culture-positive results by country were included in this updated review and meta-analysis. Prevalence ranged from 19·7 (95% CI 10·3-31·5) cases identifi ed per 100 000 individuals screened in countries with a prevalence of 50-149 cases per 100 000, to 335·9 (283·0-393·2) per 100 000 in countries with a prevalence of greater than 350 per 100 000. Substantial variation exists in the screening protocols used by each study.
Added value of this study
Migrants with a history of close or household contact with an individual with tuberculosis were at an increased risk of being detected with bacteriologically confi rmed infection at pre-entry screening. We present direct estimates of the yield of tuberculosis in applicants for student visas (85 [95% CI 75-96] cases per 100 000 individuals); although the risk of tuberculosis in students is lower than the overall detection rate, students account for a large number of cases in many low-incidence countries. Our results will enable further examination of the cost-eff ectiveness of screening of this group, with operational data from a large number of student visa applicants. We updated a meta-analysis of culture-positive cases by country of origin to include data from our study from all countries where more than 1000 migrants had been screened. Compared with the 2014 meta-analysis, the level of heterogeneity increased, and the prevalence of tuberculosis detected no longer increased with WHO prevalence of tuberculosis in the country of origin.
Implications of all the available evidence Present evidence supports the case for contact tracing and investigation in the country of origin, and improved coordination between pre-entry screening programmes and national tuberculosis programmes in the applicant's country, both of which are an increasing focus of both the UK and the USA. Our study provides additional support for recent changes to pre-entry screening policies in these two countries, since migrants screened at sites with sputum culture testing were more likely to be detected with active pulmonary tuberculosis, after adjustment for age and sex, than those screened at sites without such testing. To tackle the burden of tuberculosis in migrants, a wide-ranging approach that includes screening and treatment for latent tuberculosis infection, in addition to the existing focus on active disease, will be necessary.
For the UK tuberculosis technical instructions see https://www.gov.uk/ government/publications/uktuberculosis-technicalinstructions media; tuberculosis confi rmed by microscopy for acid-fast bacilli; tuberculosis confi rmed by culture testing on liquid or solid media and resistant to one or more anti-tuberculosis drugs; and clinically confi rmed tuberculosis.
Statistical analysis
We used Poisson regression (suitable for modelling of rareevent data) to estimate crude prevalence of the primary and secondary outcomes, calculated per 100 000 individuals screened. We also calculated estimates of prevalence adjusted by age and sex for the primary and secondary outcomes, and compared adjusted estimates for each country with WHO population prevalence in 2010. 6 To account for duplicate screens of visa applicants, all crude and adjusted estimates accounted for clustering by individual. We estimated the number needed to screen to detect one case as the inverse of screening prevalence, under the assumption of a comparator of no tuberculosis screening. We built a multivariable logistic regression model to identify risk factors for the primary outcome, and present fi nal results of this model as odds ratios (ORs), with 95% CIs and p values. We estimated population attributable fractions (appendix p 8) with multivariable models, and interpreted the results as the proportion of incident tuberculosis attributable to each risk factor, after controlling for each other and for known confounders. We used Stata version 13 for all statistical analyses.
Our main analysis included migrants screened at sites where culture and smear testing was done on all sputum samples. Sensitivity analysis included all migrants screened before entry by the IOM, irrespective of whether culture testing was available at the screening site, to examine the eff ect of the introduction of sputum testing on the prevalence of bacteriologically confi rmed cases of tuberculosis. At the start of the pilot programme, culture testing was not universally available at IOM screening clinics. As a secondary analysis, we used multivariable logistic regression to examine whether the introduction of culture testing was associated with an increased risk of bacteriologically confi rmed tuberculosis after controlling for age, sex, WHO prevalence in the country of origin, self-report of close or household contact with a case of tuberculosis before screening, and visa category.
We also updated our previous systematic review and meta-analysis of pre-entry screening for tuberculosis. 2 Additional details on the method used are provided in appendix p 5.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Data are n (%) or prevalence (95% CI). *6232 applicants were unable or unwilling to have chest radiography. †No abnormality, or abnormality classifi ed in groups 1, 2, and 3. number needed to screen to detect one case in this pilot programme was 1087 (990-1190). The crude prevalence of clinically diagnosed cases, excluding laboratory confi rmed cases, was 3 (2-4) per 100 000. The overall prevalence of culture-confi rmed samples with resistance to one or more tuberculosis drugs was 3 (2-5) per 100 000 applicants screened or 5 (1·18%) of 422 cultureconfi rmed samples that underwent drug susceptibility testing.
Crude prevalence of bacteriologically confi rmed tuberculosis was highest in migrants from countries with a WHO-estimated prevalence of 150-349 per 100 000 (225 per 100 000), and screening of 444 (379-521) applicants was necessary to detect one case. By contrast, crude prevalence of these cases was lower in migrants from countries with WHO-estimated prevalence of more than 350 per 100 000 (72 [64-81] per 100 000).
In Eritrea and Tanzania, age-adjusted and sex-adjusted estimates for prevalence of bacteriologically confi rmed tuberculosis in screened visa applicants were consistent with WHO-estimated population prevalence in 2010 (fi gure 2; see crude rates in appendix p 10). Compared with WHO population prevalence, age-adjusted and sexadjusted prevalence estimates of such cases were higher in Thailand and lower in all other countries.
Multivariable logistic regression analysis (table 2) showed strong evidence that, after adjustment for age, sex, and clustering by individual, having close or household contact with an individual with tuberculosis was associated with an increased risk of bacteriologically confi rmed tuberculosis at pre-entry screening (OR 11·6, 95% CI 7·0-19·3; p<0·0001), with a population attributable fraction of 2·68%. Compared with migrants from countries with a WHO prevalence of 150-349 per 100 000, migrants from countries with a prevalence of 40-149 per 100 000 were at reduced risk of bacteriologically confi rmed tuberculosis at pre-entry screening (0·1, 0·1-0·3; p<0·0001), as were those from countries with a prevalence greater than 350 per 100 000 (0·3, 0·3-0·4; p<0·0001), after adjustment for age and sex.
We did a sensitivity analysis to examine the prevalence of the primary and secondary outcomes when including all migrants screened before entry, not only those attending clinics where culture and smear testing was done on all sputum samples. 692 232 migrants were screened under this protocol, and the overall prevalence of bacteriologically confi rmed tuberculosis was 75 (69-82) per 100 000 applicants screened (appendix p 6), which was lower than that in our primary analysis, but increased over time.
In multivariable analysis adjusted for age, sex, WHO prevalence in country of origin, self-report of close or household contact with a case of tuberculosis before screening, and visa category, migrants screened at sites where sputum culture testing was done on all samples were associated with increased odds of having bacteriologically confi rmed tuberculosis (OR 2·4, 1·9-3·0, p<0·0001; table 3), compared with those being screened at sites where culture testing was not routinely done.
We updated our 2014 meta-analysis 2 to compare our study results with published work. Our updated search identifi ed 257 new studies, but none met the full inclusion criteria. Inclusion of crude estimates from the UK with data from published work [8] [9] [10] [11] [12] [13] increased the level of heterogeneity, and the prevalence of culture-positive cases no longer increased with the prevalence of tuberculosis in the country of origin (fi gure 3). The summary estimates of culture-confi rmed cases were Prevalence per 100 000 population B u r k i n a F a s o B a n g la d e s h C a m b o d i a C ô t e d ' I v o i r e E r i t r e a G h a n a K e n y a L a o s N i g e r P a k i s t a n S u d a n S o m a li a T o g o T a n z a n i a T h a i la n d 
Discussion
Nearly 700 000 pre-entry screening episodes for tuberculosis were done, of which almost 500 000 were done at sites where culture testing of sputum samples was a routine practice. After adjustment for age and sex, migrants reporting close or household contact with an individual with tuberculosis, applicants screened in countries with a WHO prevalence of 151-349 per 100 000, and those applying for settlement and dependant visas had an increased risk of being detected with bacteriologically confi rmed tuberculosis. Although those reporting contact with a case of tuberculosis had high odds of activetuberculosis detection, the population attributable fraction was less than 3% in this group. These migrants are likely to benefi t from early detection and treatment in their country of origin, and our fi nding supports the role of contact tracing and investigation in the country of origin, in addition to increased coordination between pre-entry screening programmes and national tuberculosis programmes in the applicant's country.
Our study is the fi rst comprehensive analysis of UK data for pre-entry screening of migrants, and we identifi ed risk factors for tuberculosis in migrants screened before entry in several countries and estimated the number needed to screen to detect one case. The strengths of our study included the large dataset and its representativeness, resulting from a policy that required screening for all migrants applying to stay in the UK for more than 6 months. The UK technical instructions should reduce measurement error and misclassifi cation bias for exposures and outcomes, including in the classifi cation of chest radiographs because of the established system used.
A limitation of this study is that it did not include data for undocumented migrants, refugees, and those with visas for less than 6 months. Undocumented migrants might be at a higher risk of tuberculosis than individuals in this study for complex reasons-eg, malnutrition, history of living in overcrowded situations such as refugee camps, higher rates of HIV, and a disruption in access to health services. [14] [15] [16] However, these diff erences might depend on the protocols determining access to health care for these migrants, as shown by the Israeli experience. 17 Migrants who are planning to stay in the UK for more than 6 months, such as those in this study, are likely to be from higher socioeconomic backgrounds than average in their country of origin.
Close or household contact with an individual with tuberculosis might be under-reported because visa applicants might suspect it would count against their application. If this is true, then we will have underestimated the magnitude of this risk factor. Unmeasured confounding (caused by variables not collected or adjusted for) might explain diff erences between the prevalence seen in pre-entry screening and WHO population estimates. The availability of confounding variables was scarce, since the data were collected for operational visa processing and not epidemiological analysis. We therefore believe that several factors, including bias and unmeasured confounding, could explain the fi nding that tuberculosis detection was not the highest in applicants from countries with the highest WHO prevalence, and urge caution in the interpretation of this lack of trend in the UK pilot data and updated meta-analysis.
Our results might diff er from published work on preentry screening for several other reasons. First, the data presented are for migrants intending to stay for a minimum of 6 months. Second, a large proportion of migrants screened were students or young adults of working age, but no data were available from published studies that would allow adjustment of estimates. Third, not all published studies provide exact details of how culture testing was done, and the investigators of a large study 8 highlighted the fact that the procedure might not have been uniform. In our study, consistent with UK technical instructions, cases could be bacteriologically confi rmed by smear, culture, or both. Because of the UK technical instructions and quality assurance processes, such variability should not be an issue in our data. Finally, our study excluded duplicate screens in the analysis, which we believe previous studies did not undertake.
Our analysis provides strong support for the previous change to US and UK technical instructions for the inclusion of culture testing in the screening protocol. 13 The groups of migrants identifi ed as being at high risk of active tuberculosis will benefi t from improved clinical outcomes and health status as a result of early detection and treatment, and the population will also benefi t from reduced onward transmission. [18] [19] [20] At present, students are not screened as part of the US pre-entry screening programme. Although their risk of tuberculosis is lower than many other groups, they remain a substantial source of cases, and our fi ndings will enable further analyses, including updated analyses of the cost-eff ectiveness of screening programmes for students. 21 Delays introduced by the requirement for culture testing of sputum sample, which can take a minimum of 6 weeks in liquid media and 8 weeks in solid media, also pose concern-eg, such delays can result in students missing the beginning of the academic year or skilled migrants being delayed in starting work. New rapid tests with high sensitivity (eg, GeneXpert MTB/RIF system) are available and could potentially reduce these delays, but these tests should be assessed in the operational setting of pre-entry screening and compared with traditional culture methods before being widely rolled out. 22, 23 Migrants from low-prevalence countries were at a reduced risk of active tuberculosis. Countries that have pre-entry screening programmes invest public funds into the quality assurance of such screening, and therefore a threshold above which pre-entry screening is cost-eff ective should be determined. The number needed to screen to detect one case across all sites in this pilot programme was 1087 and was reduced to 444 when only migrants from countries with prevalence of 150-349 per 100 000 population were screened. Several costs were associated with this pilot screening programme, including initial set-up costs funded by the UK Government (£1·1 million at November, 2010, prices) and the cost to individual applicants, which varied across sites but was around US$50-70 in November, 2011. 24 Therefore, a cost-eff ective analysis that considers these and other relevant costs is strongly recommended. The analysis should also examine diff erent perspectives, including that of the receiving country, wider society, and an enlightened self-interest approach in which there is investment in tuberculosis control programmes overseas by a receiving country. 25, 26 Risk factors for progression to active tuberculosis need to be identifi ed, and rates of progression in those who tested negative before entry should be estimated. These data would be particularly useful in informing the possible eff ect of the introduction of pre-entry screening for latent tuberculosis. 27 Unmeasured confounding factors, including socioeconomic and HIV status, could be important, and eff orts should be made to obtain relevant data in an appropriately sensitive manner, compliant with information governance and public health legislation.
We identifi ed several groups of migrants at high risk of active tuberculosis at pre-entry screening. To tackle the burden of disease in this population, a wide-ranging approach that includes screening and treatment for latent tuberculosis infection is necessary; 9 however, migrants will remain at higher risk than those born in the UK because of an increased likelihood of exposure to infectious cases in the UK or when travelling back to their country of origin. 28 The inclusion of latenttuberculosis screening at one point in time would not eliminate this risk, and a more comprehensive approach should therefore be explored. This approach could include improved integration between pre-entry screening and health services after arrival, and appropriate delivery of health care and health improvement programmes, rather than focusing solely on tuberculosis. Such an approach would be welcomed, in view of the documented issues migrants have in accessing health services after arrival in the UK.
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